Sickle cell disease (SCD) is a group of inherited disorders caused by mutations in HBB,
which encodes haemoglobin subunit β. The incidence is estimated to be between 300,000 …

Hydroxyurea has many characteristics of an ideal drug for sickle cell anemia (SCA) and
provides therapeutic benefit through multiple mechanisms of action. Over the past 25 years …

Background: Researchers of sickle cell disease have traditionally used health care
utilization as a proxy for pain and underlying vaso-occlusion. However, utilization may not …

Background Sickle cell disease (SCD) is a chronic disease associated with high degrees of
morbidity and increased mortality. Health-related quality of life (HRQOL) among adults with …

Objective: Depression and anxiety are common in sickle cell disease (SCD) but relatively
little is known about their impact on SCD adults. This study measured prevalence of …

Background This study explored the blood transfusion patterns, SCD complications,
utilization of iron chelation therapies (ICT), healthcare resource use, and costs in pediatric …

Blood transfusion plays a prominent role in the management of patients with sickle cell
disease (SCD), but causes significant iron overload. As transfusions are used to treat the …

Patients with sickle cell disease (SCD) experience a disproportionately high use of health
care resources. Several studies have examined depression and other negative mood states …

Background Sleep disturbance and depression are commonly encountered in primary care.
In sickle cell disease, depression is associated with pain, poor treatment compliance, and …

Clinical experts have expressed concern about underutilization of sickle cell disease (SCD)
therapies, including hydroxyurea, prophylactic antibiotics, iron chelation, bone marrow …